JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2007, 56(1):5-10

Deep vein thromboembolism in malignant diseases

M. Zemková1,2, R. H. B. Meyboom1,3, M. Blažek4, J. Kotlářová2, J. Vlček2, L. Jebavý4,5
1 Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring Uppsala, Sweden
2 Department of Social and Clinical Pharmacy, School of Pharmacy Hradec Králové, Charles University Prague, Czech Republic
3 Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht, the Netherlands
4 Department of Clinical Haematology of the Second Internal Clinic in the University Hospital and Medical Faculty of Charles University Hradec Králové, Czech Republic
5 Department of Field Internal Medicine, Faculty of Military Health Sciences, University of Defence Hradec Králové, Czech Republic

Tumourous diseases are associated with haemorrhagic as well as thrombotic complications. Trousseau described in 1865 a mutual association between tumourous diseases and venous thromboembolism. As many as 15-20 % patients with venous thromboembolism have an undetected malignity, which equals a prevalence of 2-3 % in the population. From this ensues the relative risk of a newly diagnosed malignity which is higher during the first year after venous thromboembolism. Migrating thrombophlebitis is a relatively specific sign in tumours, in particular in pancreatic tumours. In the pathogenesis of venous thromboembolisms in tumourous diseases, the following factors play a significant part: elevated coagulation parameters, reduced fibrinolysis, frequent immobilization, surgical operations in the case history, chemotherapy, hormonal therapy and central venous catheters. Conventional long term management of VTE involves the use of vitamin K antagonists, such as warfarin, to reduce the risk of recurrence. Recent evidence-based approach in long term management of VTE in patients with tumorous disease shows that the use of LMWH offers an effective alternative to VKAs with higher efficacy, without a significantly increased risk of bleeding, and without the need for regular laboratory monitoring.

Keywords: haemostasis; deep venous thrombosis; tumourous diseases; pathogenesis; treatment; unfractionated, low molecular weight heparin; warfarin

Received: December 7, 2006; Accepted: December 18, 2006; Published: January 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zemková M, Meyboom RHB, Blažek M, Kotlářová J, Vlček J, Jebavý L. Deep vein thromboembolism in malignant diseases. Čes. slov. farm. 2007;56(1):5-10.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kirwan, C. C., Nath, E., Byrne, G. J., McCollum, C. N.: BMJ, 2003; 327, 597-598.
    2. Zemková, M., Vlček, J.: Klinická farmacie a farmakologie, 2006; 20, 6-10.
    3. Prandoni, P., Lensing, A. W. A., Cogo, A. et al.: : Ann. Intern. Med., 1996; 125, 1-7. Go to original source... Go to PubMed...
    4. Sørensen, H. T., Mellemkjaer, L., Olsen, J. H., Baron, J. A.: N. Engl. J. Med., 2000; 343, 1846-1850. Go to original source... Go to PubMed...
    5. Prandoni, P., Lensing, A. W. A., Büller, H. R. et al.: : N. Engl. J. Med., 1992; 327, 1128-1133. Go to original source... Go to PubMed...
    6. Geerts, W., Pineo, G. F., Heit, G. A. et al.: Chest, 2004; 126, 338S-400S.
    7. Peuscher, F. W.: Neth. J. Med., 1981; 24, 23-35. Go to original source...
    8. Thompson, C. M., Rodgers, R. L.: Am. J. Med. Sci., 1992; 223, 469-476.
    9. Lee, A. Y. Y., Levine, M. N.: Semin. Thromb. Hemost., 1999; 25, 137-145. Go to original source... Go to PubMed...
    10. Verso, M., Agnelli, G.: J. Clin. Oncol., 2003; 21, 36653675. Go to original source... Go to PubMed...
    11. Naninga, P. B., van Tuenenbroek, A., Veenhof, C. H. N. et al.: Thromb. Haeemost., 1990; 64, 361-364. Go to original source...
    12. Falanga, A., Rickles, F. R.: Semin. Thromb. Hemost., 1999; 25, 173-182. Go to original source... Go to PubMed...
    13. Goldenberg, N., Kahn, S. R., Solymoss, S.: J. Clin. Oncol., 2003; 21, 4194-4199. Go to original source... Go to PubMed...
    14. Falanga, A., Barbui, T., Rickles, F. R., Levine, M. N.: Thromb. Haemost., 1993; 70, 540-542. Go to original source...
    15. Levine, M. N., Hirsh, J. et al.: N. Engl. J. Med., 1998; 333, 1404-1407.
    16. Saphner, T., Tormey, D. C., Gray, R.: J. Clin. Oncol., 1991; 9, 286-294. Go to original source... Go to PubMed...
    17. Pritchard, K. I., Paterson, A. H. G., Paul, N. A. et al.: J. Clin. Oncol., 1996; 14, 2731-2737. Go to original source... Go to PubMed...
    18. Otten, H. M. M. B., Mathijssen, J., ten Cate, H. et al.: Arch. Intern. Med., 2004; 164, 190-194. Go to original source... Go to PubMed...
    19. Clagett, G. P., Reisch, J. S.: Ann. Surg., 1998; 208, 227240.
    20. Prandoni, P.: Thromb. Haemost., 1997; 78, 141-144. Go to original source...
    21. Samama, M. M.: Arch. Intern. Med., 2000; 160, 34153420. Go to original source... Go to PubMed...
    22. Goldhaber, S. Z., Tapson, V. F.: Am. J. Cardiol., 2004; 93, 259-262. Go to original source... Go to PubMed...
    23. Baron, J. A., Gridley, G., Weiderpass, E. et al.: Lancet, 1998; 351, 1077-1080. Go to original source... Go to PubMed...
    24. Nordström, M., Lindblad, B., Anderson, H. et al.: BMJ, 2004; 318, 891-894.
    25. Sørenson, H. T., Mellemkjaer, L., Olsen, J. H., Nielsen, G. L.: N. Engl. J. Med., 1998; 338, 1169-1173. Go to original source... Go to PubMed...
    26. Cornuz, J., Pearson, S. D., Creager, M. A. et al.: Ann. Intern. Med., 1996; 125; 785-793. Go to original source... Go to PubMed...
    27. Hettiarachchi, R. J. K., Lok, J., Prins, M. H. et al.: Cancer 1998; 83, 180-185. Go to original source...
    28. Bastounis, E. A., Karayiannakis, A. J., Makri G. G. et al.: J. Intern. Med., 1996; 239, 153-156. Go to original source... Go to PubMed...
    29. Monreal, M., Lafoz, E., Casals, A. et al.: Cancer, 1991; 67, 541-545. Go to original source...
    30. Fennerty, T.: BMJ, 2001; 323, 704-705.
    31. Piccioli, A., Lensing, A. W. A., Prins, M. H. et al.: J. Thromb. Haemost., 2004; 2, 884-889. Go to original source... Go to PubMed...
    32. Büller, H. R., Agnelli, G., Hull, R. D. et al.: Chest, 2004; 126, 401S-428S.
    33. Prandoni, P., Lensing, A. W. A., Piccioli, A. et al.: Blood, 2002; 100, 3484-3488. Go to original source... Go to PubMed...
    34. Ansell, J., Hirsh, J., Poller, L. et al.: Chest, 2004; 126, 204S-233S.
    35. Huber, O., Bounameaux, H., Borst, F. et al.: Ach. Surg., 1992; 127, 310-313. Go to original source... Go to PubMed...
    36. Cohen, A. T., Wagner, M. B., Mohamed, M. S.: Am. J. Surg., 1997; 174, 1-5. Go to original source... Go to PubMed...
    37. Berqvist, D., Burmark, U. S., Frisell, J. et al.: Semin. Thromb. Hemost., 2000; 26, 19-24.
    38. Berqvist, D., Agnelli, G., Cohen, A. T. et al.: N. Engl. J. Med., 2002; 346, 975-980. Go to original source... Go to PubMed...
    39. Rasmussen, M. S., Wille-Jørgensen, P., Jørgensen, L. N.: San Diego, USA, Proceedings of America Society of Haematology 2003 (abstract).
    40. Lee, A. Y. Y., Levine, M. N., Baker, R. T. et al.: N. Engl. J. Med., 2003; 349, 146-153. Go to original source... Go to PubMed...
    41. Hirsh, J., Lee, A. Y. Y.: Blood, 2002; 99, 3102-3110. Go to original source... Go to PubMed...
    42. Pini, M., Manotti, C., Pattacin, C. et al.: Thromb. Haemost., 1994; 72, 191-197. Go to original source...
    43. Das, S. K., Edmondson, R. A. et al.: World J. Surg., 1996; 20, 521-526. Go to original source... Go to PubMed...
    44. Lopaciuk, S., Bielska-Falda, M., Noszcyk, W. et al.: Thromb. Haemost., 1999; 81, 26-31. Go to original source...
    45. Meyer, G., Marjanovic, Z., Valcke, J. et al.: Arch. Intern. Med., 2002; 162; 1729-1735. Go to original source... Go to PubMed...
    46. Koopman, M. M. W., Prandoni, P., Piovella, F. et al.: N. Engl. J. Med., 1996; 334, 682-687. Go to original source... Go to PubMed...
    47. Gould, M. K., Dembitzer, A. D., Doylke, R. L. et al.: Ann. Intern. Med., 1999; 130; 800-809. Go to original source... Go to PubMed...
    48. Gould, M. K., Belt, A. G. M., Prins, M. H. et al.: Cochrane Database Syst Rev 2005; CD001600.
    49. Dolovich, L. R., Ginsberg, J. S., Douketis, J. D. et al.: Arch. Intern. Med., 2000; 160; 188. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.